Abstract
Hepatitis C virus (HCV) infection is now considered a systemic disease due to the
occurrence of extra-hepatic manifestations. Among these, the renal involvement is
frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic
kidney disease (CKD) and negatively affects the prognosis of renal patients. In the
last few years, availability of more specific and effective drugs against HCV has
dramatically changed the clinical course of this disease. These drugs may provide
further advantages in the CKD population as a whole by reducing progression of renal
disease, mortality rate and by increasing the survival of graft in renal transplant
recipients. The strict pathogenetic and prognostic link between HCV infection and
CKD requires an ongoing relationship among the healthcare professionals involved in
the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved
in the care of this high-risk population in Italy have organized a joint expert panel.
The aim of the panel is to produce a position statement that can be used in daily
clinical practice for the management of HCV infected patients across the whole spectrum
of renal disease, from the conservative phase to renal replacement treatments (dialysis
and transplantation). Sharing specific evidence-based expertise of different professional
healthcare is the first step to obtain a common ground of knowledge on which to instate
a model for multidisciplinary management of this high-risk population. Statements
cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related
renal risk, staging of liver disease in patients with CKD, prevention of transmission
of HCV in hemodialysis units, treatment of HCV infection and management of HCV in
kidney transplantation.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int Suppl. 2013; 3: 1-150
- Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey.Nephrol Dial Transpl. 2015; 30: 806-814
- Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital.BMC Nephrol. 2009; 10: 24
- Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross sectional study from Italy.Am J Kidney Dis. 2008; 52: 444-453
- Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease.J Viral Hepat. 2014; 21: 706-715
- Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection.Hepatol Int. 2012; 6: 369-378
- Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004–2011.J Viral Hepat. 2015; 22: 906-913
- Evaluation of renal function in patients with cirrhosis: where are we now?.World J Gastroenterol. 2014; 20: 2533-2541
- Chronic kidney disease prevalence in the general population: heterogeneity and concerns.Nephrol Dial Transpl. 2016; 31: 331-335
- International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality.J Am Soc Nephrol. 2006; 17: 3510-3519
- Primary prevention of cardiovascular disease with a Mediterranean diet.N Engl J Med. 2013; 368: 1279-1290
- Mediterranean diet, kidney function, and mortality in men with CKD.Clin J Am Soc Nephrol. 2013; 8: 1548-1555
- Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Circulation. 2003; 108: 2154-2169
- Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.Lancet. 2012; 380: 807-814
- Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention.Kidney Int. 2006; 69: 538-545
- Prognosis of CKD patients receiving outpatient nephrology care in Italy.Clin J Am Soc Nephrol. 2011; 6: 2421-2428
- The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care.Kidney Int. 2012; 82: 482-488
- Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care.PLoS One. 2015; 10e0127071
- Health care utilization among patients with chronic kidney disease.Kidney Int. 2002; 62: 229-236
- Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med. 2004; 351: 1296-1305
- CKD and risk for hospitalization with infection: the atherosclerosis risk in communities (ARIC) study.Am J Kidney Dis. 2017; 69: 752-761
- Rate of kidney function decline and risk of hospitalizations in stage 3A CKD.Clin J Am Soc Nephrol. 2015; 10: 1946-1955
- KDIGO Clinical practice guideline for acute kidney injury.Kidney Int Suppl. 2012; 2: 1-138
- A Meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury.Am J Kidney Dis. 2015; 66: 602-612
- Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis.J Viral Hepat. 2016; 23: 32-38
- Acute renal failure in critically ill HIV-infected patients.Crit Care. 2007; 11: 404
- Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients.J Acquir Immune Defic Syndr. 2006; 42: 368-372
- The impact of hepatitis C virus co-infection on HIV-related kidney disease: a systematic review and meta-analysis.AIDS. 2008; 22: 1799-1807
- Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus co-infection.AIDS Patient Care. 2011; 25: 135-141
- Chronic kidney disease after acute kidney injury: a systematic review and metaanalysis.Kidney Int. 2012; 81: 442-448
- Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury.Kidney Int. 2012; 81: 477-485
- Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study.Clin J Am Soc Nephrol. 2014; 9: 1586-1593
- Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis.Am J Med. 2007; 120: 1063-1070
- An economic evaluation of early versus late referral of patients with progressive renal insufficiency.Am J Kidney Dis. 2001; 38: 1122-1128
- ISG-EHCV. International therapeutic guidelines for patients with HCVrelated extrahepatic disorders. A multidisciplinary expert statement.Autoimmun Rev. 2017; 16: 523-541
- Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus.Am J Nephrol. 1993; 13: 300-304
- Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.Ann Intern Med. 2006; 144: 735-741
- Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease.Am J. Kidney Dis. 2013; 61: 623-637
- Hepatitis C virus: from entry to renal injuryfacts and potentials.Nephrol Dial Transpl. 2007; 22: 1840-1848
- Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.Arthritis Rheum. 1999; 42: 2204-2212
- Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.PLoS Pathog. 2014; 10e1004424
- Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases.J Viral Hepat. 2000; 7: 23-29
- Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.Hepatology. 1997; 25: 1237-1244
- Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection.Expert Rev Clin Immunol. 2015; 11: 15-31
- Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis.Nephrol Dial Transpl. 1996; 11: 25-30
- TLR4 links podocytes with the innate immune system to mediate glomerular injury.J Am Soc Nephrol. 2008; 19: 704-713
- Novel role of toll-like receptor 3in hepatitis C-associated glomerulonephritis.Am J Pathol. 2006; 168: 370-385
- Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.Hepatology. 2017; 66: 784-793
- Hepatitis C virusassociated tubulointerstitial injury.Am J Kidney Dis. 2003; 41: 767-775
- Detection of viruslike particles in liver biopsies from HCV-infected patients.Res Virol. 1998; 149: 311-314
- HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis.Virology. 2005; 334: 10-16
- Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.N Engl J Med. 1993; 328: 465-470
- Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan.J Am Soc Nephrol. 1995; 6: 220-223
- Therapy of hepatitis C virus-associated glomerulonephritis: current approaches.J Nephrol. 2008; 21: 813-825
- Hepatitis C and renal disease: an update.Am J Kidney Dis. 2003; 42: 631-657
- The clinical and morphologic spectrum of renal cryoglobulinemia.Med (Baltim). 2002; 81: 398-409
- International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.Autoimmun Rev. 2016; 15: 1145-1160
- Glomerulonephritis in autopsy cases with hepatitis C virus infection.Intern Med. 1998; 37: 836-840
- Hepatitis C associated glomerulonephritis.Am J Nephrol. 1995; 15: 407-410
- Hepatitis C virus infection and membranous glomerulonephritis.Nephron. 1991; 59: 319-320
- Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin.Clin Nephrol. 2013; 80: 231-234
- Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis.Ren Fail. 2013; 35: 1182-1185
- Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection.Intern Med. 2010; 49: 2531-2532
- IgA nephropathy associated with hepatitis C virus infection.Nephron. 1995; 69: 354
- Hepatitis C as a potential cause of IgA nephropathy.Indian J Nephrol. 2013; 23: 143-145
- Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy.Am J Kidney Dis. 1993; 22: 367-377
- Fibrillary glomerulonephritis associated with hepatitis C viral infection.Am J Kidney Dis. 1997; 29: 132-135
- Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection.Clin Nephrol. 2003; 60: 364-368
- Fibrillary glomerulopathy.Kidney Int. 1998; 53: 1421-1429
- Kidney disease in patients with chronic hepatitis C.Curr Gastroenterol Rep. 2001; 3: 79-83
- Hepatitis C virus and kidney disease.J Hepatol. 2008; 49: 613-624
- Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation.Transplantation. 1998; 65: 741-744
- Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys.Am J Kidney Dis. 1996; 28: 752-758
- Impact of hepatitis B and C virus on kidney transplantation outcome.Hepatology. 1999; 29: 257-263
- De novo membranoproliferative glomerulonephritis in hepatitis C virus-infectedrenal allograft recipients.Transplantation. 1995; 59: 1676-1682
- Interferon therapy in haemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course.Nephron Clin Pract. 2005; 100: c133-c139
- Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients.Transplantation. 1997; 63: 1634-1639
- Hepatitis C infection is acquired pre-ESRD.Am J Kidney Dis. 2005; 45: 684-689
- Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES.Dig Dis Sci. 2016; 61: 930-936
- Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis.Ann Hepatol. 2018; 17: 364-391
- Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.Am J Kidney Dis. 2001; 38: 1009-1015
- High ALT. levels predict viremia in anti-HCV positive HD patients if a modified normal range of ALT is applied.Clin Nephrol. 2000; 54: 151-156
- Hepatitis C virus: virology, diagnosis and treatment.World J. Hepatol. 2015; 7: 1377-1389
- Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.J Viral Hepat. 2001; 8: 87-95
- Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods.J Clin Microbiol. 1998; 36: 1711-1715
- Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.Vox Sang. 1995; 68: 15-18
- High false-negative rate of anti-HCV among Egyptian patients on regular haemodialysis.Hemodial Int. 2012; 16: 420-427
- KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.Kidney Int. 2008; 73: S1-S99
- EASL recommendations on treatment of hepatitis C 2018.J Hepatol. 2018; https://doi.org/10.1016/j.jhep.2018.03.026
- Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in haemodialysis patients with chronic HCV infection.Am J Gastroenterol. 2000; 95: 490-496
- Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.Hepatology. 2013; 57: 1333-1342
- Hepatitis C is a predictor of poorer renal survival in diabetic patients.Diabetes Care. 2005; 28: 2187-2191
- Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.Am J Nephrol. 2010; 32: 311-316
- Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis.J Med Virol. 2016; 88: 487-497
- High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease.Kidney Int. 2017; 92: 703-709
- Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease.Liver Transpl. 2014; 20: 25-34
- Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.Hepatol Res. 2011; 41: 946-954
- Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.Hepatology. 2014; 59: 1293-1302
- Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.Gut. 2015; 64: 495-503
- A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease.Med (Baltim). 2015; 94e1334
- Microalbuminuria and renal insufficiency in chronic hepatitis C virus infection.Gastroenterol Hepatol. 2012; 35: 309-316
- Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.Eur J Clin Microbiol Infect Dis. 2016; 35: 1511-1520
- Hepatitis C virus RNA localization in human carotid plaque.J Clin Virol. 2010; 47: 72-75
- Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.World J Gastroenterol. 2014; 20: 3410-3417
- Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.Hepatology. 2015; 61: 1495-1502
- The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis.Pathophysiol Haemost Thromb. 2005; 34: 274-278
- Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial.Am J Kidney Dis. 2011; 57: 850-855
- Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection.Hepatology. 2007; 46: 307-314
- Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients.Clin J Am Soc Nephrol. 2011; 6: 1057-1065
- Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.Nephron Clin Pract. 2011; 117: c289-295
- New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.Hepatol Int. 2017; 12: 34-43
- Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors.BMC Infect Dis. 2012; 12: 265
- SHECTS multi-centre Spanish Study: liver situation of patients with chronic hepatitis from HCV on renal replacement therapy with haemodialysis.Nefrologia. 2013; 33: 188-195
- Hepatitis C infection is very rarely treated among haemodialysis patients.Am J Nephrol. 2013; 38: 405-412
- Risk factors for hepatitis C virus seropositivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria.Pan Afr Med J. 2014; 19: 305
- Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors.Saudi J Kidney Dis Transpl. 2014; 25: 672-679
- Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in haemodialysis patients.Virol J. 2015; 12: 8
- Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study.BMC Public Health. 2015; 15: 192
- Hepatitis B virus and hepatitis C virus co-infection in haemodialysis patients: a retrospective study from a tertiary care hospital of North India.J Nat Sci Biol Med. 2016; 7: 72-74
- Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks.Int J Artif Organs. 2015; 38: 471-480
- Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008.Ann Intern Med. 2009; 150: 33-39
- Hepatitis: control measures for hepatitis B in dialysis centers.US Department of Health, Education and Welfare, Altlanta, GA1977 (HEW publication no. (CDC) 78-8358)
Centers for Disease Control and Prevention (2001) Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR Morb Mortal Wkly Rep 50:1–43.
Centers for Disease Control and Prevention (2008) Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep 57:875–876.
- Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort in a quality improvement report.Am J Kidney Dis. 2013; 62: 322-330
- A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance.Nephrol Dial Transpl. 2005; 20: 1164-1171
- The changing epidemiology of hepatitis C virus infection in haemodialysis: European multicentre study.Nephrol Dial Transpl. 2004; 19: 904-909
- Hepatitis C virus outbreak in a haemodialysis unit: learning from failures.J Hosp Infect. 2016; 94: 249-252
- Notes from the field: hepatitis C outbreak in a dialysis clinic—Tennessee, 2014.MMWR Morb Mortal Wkly Rep. 2016; 64: 1386-1387
- A large outbreak of hepatitis C virus infections in a haemodialysis clinic.Infect Control Hosp Epidemiol. 2016; 37: 125-133
- Healthcareassociated hepatitis B and C outbreaks (≥ 2 cases) reported to the Centers for Disease Control and Prevention (CDC) 2008-2016.2017 (https://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbrea ktable.htm. Accessed 4 Aug 2017)
- CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing haemodialysis.Am J Transpl. 2016; 16: 1633-1634
- Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic haemodialysis patients.Infect Control Hosp Epidemiol. 2011; 32: 415-424
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.Cochrane Database Syst Rev. 2016; 8CD006420
- The role of haemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran: a multicentre prospective interventional study.BMC Nephrol. 2004; 5: 13
- Patterns of hepatitis C prevalence and seroconversion in haemodialysis units from three continents: the DOPPS.Kidney Int. 2004; 65: 2335-2342
- Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region.Am J Kidney Dis. 2006; 48: 629-637
- Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group.Kidney Int. 1998; 53: 1022-1025
- Prevention of hepatitis C virus in dialysis units.Nephron. 1995; 70: 301-306
- Detection of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive patients.Nephron. 1994; 68: 140
- Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis.J Med Virol. 2008; 80: 1195-1201
- Biological dynamics of viral load in hemodialysis patients with hepatitis C virus.Am J Kidney Dis. 2000; 35: 122-129
- Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay.Am J Kidney Dis. 1998; 31: 647-654
- Serum alanine aminotransferase in hepatitis C screening of patients on haemodialysis.Am J Kidney Dis. 2001; 37: 308-315
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals.Hepatology. 2013; 58: 428-438
- New hepatitis C therapies: the toolbox, strategies, and challenges.Gastroenterology. 2014; 146: 1176-1192
- Direct-acting antivirals: the endgame for hepatitis C?.Curr Opin Virol. 2017; 24: 31-37
- Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease.J Nephrol. 2018; 31: 1-13
- Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.Expert Rev Gastroenterol Hepatol. 2018; 12: 9-17
- Efficacy of Direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease.Gastroenterology. 2016; 150: 1590-1598
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.Lancet. 2015; 386: 1537-1545
- Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment.N Engl J Med. 2017; 377: 1448-1455
- The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment.Liver Int. 2016; 36: 791-793
- Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study.Hepatology. 2017; 66: 1090-1101
- Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.Liver Int. 2016; 36: 807-816
- Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Liver Int. 2017; 37: 974-981
- Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.Kidney Int. 2004; 65: 2335-2342
- Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis.Transplantation. 2013; 95: 943-948
- Markers of inflammation before and after renal transplantation.Transplantation. 2005; 80: 47-51
- Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study.Nephrol Dial Transpl. 2016; 31: 1168-1174
- Effect of kidney transplantation on outcomes among patients with hepatitis C.J Am Soc Nephrol. 2011; 22: 1152-1160
- Meta-analysis of observational studies: hepatitis C and survival after renal transplant.J Viral Hepat. 2014; 21: 314-324
- Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States.Transplantation. 2017; https://doi.org/10.1097/TP.0000000000001953
- Hepatitis C and its impact on renal transplantation.Nat Rev Nephrol. 2015; 11: 172-182
- Hepatitis C treatment in patients with kidney disease.Kidney Int. 2013; 84: 874-879
- The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.J Hepatol. 2007; 46: 768-774
- Efficacy and safety of sofosbuvir-based antiviral therapy to treat Hepatitis C Virus Infection after kidney transplantation.Am J Transpl. 2016; 16: 1474-1479
- Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents.Am J Transpl. 2016; 16: 1588-1595
- Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic Hepatitis C Virus Infection.PLoS One. 2016; 11: e0158978
- DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.Transpl Int. 2016; 29: 999-1007
- Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents.Transplantation. 2017; 101: 1704-1710
- Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial.Ann Intern Med. 2017; 166: 109-117
- Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.Clin Transpl. 2017; 31e12941https://doi.org/10.1111/ctr.12941
- MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection.J Hepatol. 2017; 66: S90-S91
- Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.J Hepatol. 2017; 66: 718-723
- Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up.Transpl Int. 2018; https://doi.org/10.1111/tri.13118
- Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment.Drug Saf. 2016; 39: 589-611
- Primary biliary cirrosis by DAAs-induced HCV clearance: a biological proof of concept.Ther Adv Chronic Dis. 2018; 9: 121-123
- HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs).J Nephrol. 2018; 31: 185-187
- Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients.Am J Kidney Dis. 2012; 60: 112-120
- Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus + renal allografts.Transplantation. 2015; 99: 1192-1196
- Race, risk, and willingness of end-stage renal disease patients without hepatitis C (HCV) to accept an HCV-infected kidney transplant.Transplantation. 2018; 102: e163-e170
- Expanding the use of hepatitis C-viremic kidney donors.Kidney Int. 2017; 92: 1031-1033
- Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Transpl Int. 2017; 30: 865-873
- Transplanting HCV-infected kidneys into uninfected recipients.N Engl J. Med. 2017; 377: 1105
- Olysio prescribing information 2017.Janssen Therapeutics, Titusville2017
- Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: the Phase II SATURN study.Transpl Infect Dis. 2017; 19e12696https://doi.org/10.1111/tid.12696
- Drug–drug interactions with the NS3/4A protease inhibitor simeprevir.Clin Pharmacokinet. 2016; 55: 197-208
- Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic hcv ns5a inhibitor velpatasvir.Clin Pharmacokinet. 2016; 55: 605-613
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf.
Article info
Publication history
Published online: September 12, 2018
Accepted:
August 9,
2018
Received:
March 28,
2018
Footnotes
☆This article is co-published in the journals Journal of Nephrology https://doi.org/10.1007/s40620-018-0523-1, Internal and Emergency Medicine https://doi.org/10.1007/s11739-018-1940-9, Infection https://doi.org/10.1007/s15010-018-1209-2 and Digestive and Liver Disease https://doi.org/10.1016/j.dld.2018.08.022.
Identification
Copyright
© 2018 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. All rights reserved.
